Annarosaria De Chiara

Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors

Giosuè Scognamiglio, Annarosaria De Chiara, Antonina Parafioriti et al. · British Journal of Cancer · 2019 · 103 citations · Full text

Somatostatin analogs and prednisone in advanced refractory thymic tumors

Giovannella Palmieri, Liliana Montella, Angelo Martignetti et al. · Cancer · 2002 · 102 citations

RD‐CODOX‐M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B‐cell lymphoma

Gaetano Corazzelli, Ferdinando Frigeri, Filippo Russo et al. · British Journal of Haematology · 2011 · 76 citations

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

Gaetano Corazzelli, Gaetana Capobianco, Manuela Arcamone et al. · Cancer Chemotherapy and Pharmacology · 2009 · 75 citations

B-cell Lymphoma, Lymphoid Neoplasia, Hematological Malignancy +8

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma

Gerardo Botti, Giosuè Scognamiglio, Laura Marra et al. · Journal of Cancer · 2017 · 49 citations · Full text

Primary Angiosarcoma, Angiogenesis, Define Pd-l1 Staining +15